Rebecca Arend is an Oncology physician affiliated with University of Alabama at Birmingham Hospital. OpenAlex indexes 426 publications with 6,853 citations (h-index 44); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
619 19th St S
Birmingham, AL 352493720
Telephone
205-934-4011Registry record last updated 1 Feb 2024.
Clinical trials
- INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Daiichi Sankyo Inc.Program year20251 payment
- Corcept TherapeuticsProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
84%Opioid Agonist46.9%Oxycodone Hcl71%Morphine Sulfate Er29%Part D<11 patientsGabapentinoids23.5%Gabapentin100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
16%Poly(ADP-Ribose) Polymerase Inhibitor16%Lynparza100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Journal of the National Comprehensive Cancer Network
2025 - Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023 - NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Shelton
University of Alabama at Birmingham Hospital
Marc Passman
University of Alabama at Birmingham Hospital
Matthew Stoll, MD, PhD
University of Alabama at Birmingham Hospital
Harrison Walker
University of Alabama at Birmingham Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”